NeuraLight Named Most Innovative AI-Driven Neurology Platform by Global Health and Pharma’s Biotechnology Awards

NeuraLight, the company digitizing neurological evaluation and care for Parkinson’s, Alzheimer’s, ALS, and Multiple Sclerosis, has been selected as the Most Innovative AI-driven Neurology Platform as part of Global Health and Pharma’s (GHP) eighth annual Biotechnology Awards.

The GHP Biotechnology Awards showcase the latest developments and most promising innovations from leading biotech companies. Leveraging proprietary computer vision and deep learning algorithms, NeuraLight’s platform pulls oculometric data from standard webcam video to objectively evaluate patients’ neurological health status.

Neurological disorders are the leading cause of disability worldwide, and yet there are little to no disease-modifying therapeutic options for these conditions. Current standards for neurological evaluation are subjective, and thus impede the pharma industry from accelerating drug development for neurodegenerative diseases. The inability of researchers to accurately, objectively, and sensitively measure disease progression impacts a number of facets of clinical monitoring and drug development, with Parkinson’s disease (PD) as a perfect example.

NeuraLight’s goal is to transform the lives of billions of people impacted by neurological diseases, by introducing and harnessing novel ocular biomarkers to address challenges in drug development. NeuraLight’s technology can be seamlessly integrated into clinical trials, offering the potential to reduce clinical trial size and length, to provide additional insight into patient response and progression, and thus to increase chances for a trial’s success.

“By harnessing the power of AI and a simple webcam, we are striving to make a real impact in the field of neurology and in the development of disease-modifying therapies for neurodegenerative disease,” said NeuraLight Chief Commercial Officer, Vivian DeWoskin. “We are pleased to be honored as the most Innovative AI Platform in Neurology by GHP. ”

Last May, NeuraLight raised a $25 million series A led by KDT with participation from Breyer Capital, Samsung Next, and existing investors. Continuing the momentum, in July, NeuraLight launched an application of the platform to evaluate ALS through a collaboration with a publicly-traded pharma company.

To learn more about NeuraLight and demo the company’s technology, please visit https://neuralight.ai/.

About NeuraLight

NeuraLight is on a mission to transform the lives of billions of people impacted by neurological disorders by digitizing neurological evaluation and care. Its AI-driven platform integrates multiple digital markers to accelerate and improve drug development, monitoring, and precision care for patients with neurological disorders. The technology driving the platform includes proprietary deep learning algorithms which automatically extract a host of digital oculometric markers from facial videos captured with a standard webcam, supporting distributed trial design. NeuraLight’s founders are repeat entrepreneurs and industry veterans (including both the co-founder of Chorus.ai and the founding CTO of Flatiron Health) leading a 35-strong team. The company is supported by renowned neurologists and two Nobel laureates as well as a stellar Scientific Advisory Board, and have raised over $30.5M to date.

Contact Information

Madalyn

Account Coordinator

VSC for NeuraLight

neuralight@vsc.co